Hints and tips:
Related Special Reports
Related Topics
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...Because the European market is saturated with the BioNTech/Pfizer and Moderna shots, it remains unclear what impact on its revenues an approval might have....
...Pfizer declined to comment, citing confidentiality, as did the Commission....
...BioNTech and Pfizer have said the patents are invalid....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
Case studies in best practice among general counsel and company legal teams in North America
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...“Nobody at Pfizer ever told Mr Dagar, who was on the ‘blinded’ side, the results of the Paxlovid trial,” he added....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...Pfizer on Tuesday raised $31bn in a jumbo-sized bond sale that will help fund the takeover....
...Meanwhile Pfizer’s own shares, down more than a fifth this year, have underperformed peers....
...Haleon declined to comment on Pfizer’s plans....
...US pharmaceutical company Pfizer sold the shots, developed with Germany’s BioNTech, for about $19 a dose under the contract signed in 2021, but the new price has not been disclosed....
...The new rules give the federal government the power to negotiate lower prices for some of the most expensive prescription drugs produced by Pfizer, Merck and other pharma companies purchased by Medicare,...
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
International Edition